Please login to the form below

Not currently logged in

Gilead steps into breach left by AbbVie as Galapagos' partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

Gilead headquarters 

Gilead Sciences has earmarked $2bn to take a stake in Belgium's Galapagos and buy into its filgotinib drug candidate for rheumatoid arthritis.

The deal includes an upfront fee of $300m and a $425m, 15% stake in Galapagos, along with further payments of up to $1.35bn from milestones, shared profits and royalties if filgotinib - a JAK1 inhibitor - makes it through to the market.

Gilead has swooped in on the opportunity to partner filgotinib just a few weeks after Galapagos' former collaborator AbbVie handed back rights to the drug in order to focus on its in-house JAK inhibitor ABT-494.

Both filgotinib and ABT-494 are being developed to challenge Pfizer's Xeljanz (tofacitinib), which is the only JAK inhibitor currently approved for sale as a rheumatoid arthritis treatment and is growing strongly, with sales rising more than 70% to $351m in the first nine months of the year.

After AbbVie exited the alliance, Galapagos said filgotinib is the most selective JAK1 inhibitor and demonstrated "best-in-class efficacy and safety in RA" in a 24-week phase IIb study involving 877 patients. 

Galapagos' chief executive Onno van de Stolpe said at the time that the company was disappointed by the abrupt nature of AbbVie's decision and pledged to find a new partner as a matter of urgency "so that we jointly can prepare and execute the meetings with the FDA and EMA". 

The company has said it intends to start a phase III programme for the drug in 2016 in both RA and Crohn's disease, with FDA meetings scheduled to take place in March. Xeljanz was unable to show efficacy in an earlier clinical trial involving Crohn's disease patients.
For Gilead, filgotinib will sit at the heart of the inflammation therapeutic category which it is developing alongside its established HIV and hepatitis C virus (HCV) franchises, both of which have grown into multi-billion dollar franchises. 

Gilead has a matrix metalloproteinase (MMP) 9 inhibitor in phase II testing for Crohn's and ulcerative colitis, and in phase I for RA. Another drug - Syk inhibitor GS-9876 - is also in early-stage clinical testing for arthritis.

Under the terms of the agreement, Galapagos will fund 20% of the global development of filgotinib, and has retained co-promotion/profit-sharing rights to the drug in the UK, Germany, France, Italy, Spain, Belgium, the Netherlands and Luxembourg.

"The co-development and co-promotion aspects of this collaboration bring us into the next phase of the company's evolution," said van de Stolpe.

Article by
Phil Taylor

18th December 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...